We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 470

IP monitor - a healthy development? A review of CIPO’s new “medical method” examination guidelines

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 31 2015

On March 18, 2015 the Canadian Intellectual Property Office (“CIPO”) issued a Patent Notice: Revised Examination Practice Respecting Medical Uses

Canada PM(NOC) decision: Federal Court judge criticizes “very sketchy” disclosure in a CIALIS patent

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • March 30 2015

On February 2, 2015 Justice de Montigny of the Federal Court released his judgment and reasons in Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC

Claims that involve a fixed dosage and schedule can constitute patentable subject matter

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • March 26 2015

The Canadian Intellectual Property Office (CIPO) has just issued a revised guidance for the examination of patent applications featuring medical use

Federal Court declares omeprazole formulation patent valid and infringed

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 25 2015

On March 16, 2015, Justice Barnes of the Federal Court issued his decision in AstraZeneca Canada Inc. et al v. Apotex Inc., 2015 FC 322, declaring

Canadian patent law: 2014 year in review

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • March 18 2015

This article summarises noteworthy Canadian patent law decisions and developments from 2014. Court of Appeal addresses patent utility in Celebrex The

Application for an order of prohibition dismissed for formulation patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 18 2015

The Court found that Mylan’s allegations of non-infringement and obviousness were justified. As a result, the application for prohibition was

Patents found obvious; subsequent appeal moot

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 6 2015

Janssen Inc (Janssen) brought two Applications pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations for orders

Expert opinion as to what “one would expect” is speculation, not evidence

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice

Formulation patent allegations of non-infringement, obviousness and lack of utility justified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 2 2015

Servier sought a prohibition order against Apotex in relation to its DIAMICRON MR gliclazide product. The application was dismissed. The patent at

Application for an order of prohibition is dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 23 2015

The Court found that Teva’s allegation of obviousness was justified. As a result, the application was dismissed